Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELISPOT-guided CNI-based versus CNI-free immunosuppression after low-risk kidney transplantation
2007-002378-68Phase 2Active
- Sponsor
- Nephrology Service of Bellvitge University Hospital
- Start
- Oct 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of sirolimus, tacrolimus, mycophenolate mofetil and antithymocyte globulin in kidney allograft rejection (2 arms), sponsored by Nephrology Service of Bellvitge University Hospital. Primary endpoints: Cumulative biopsy-confirmed acute rejection at 6 months and Cumulative biopsy-confirmed acute rejection at 12 months. Started Oct 2007; status: active.
02
Drugs
sirolimustacrolimusmycophenolate mofetilantithymocyte globulin
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2007-002378-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002378-68.